Impacts of a Specific Cyclooxygenase-2 Inhibitor on Pressure Overload–Induced Myocardial Hypertrophy in Rats


  • Zhixiang Xie Department of Emergency, Guangzhou Red Cross Hospital, the Fourth Affiliated Hospital of Jinan University, the First Affiliated Hospital of Jinan University, Guangzhou, Guangdong, China
  • Shuyin Wang Department of Emergency, Women and Children Medical Center, Guangzhou, Guangdong, China
  • Zijing Liang Department of Emergency, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China
  • Liangbo Zeng
  • Rongde Lai Department of Emergency, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China
  • Zheng Ye Department of Emergency, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China
  • Pinhu Liao Youjiang Medical University for Nationalities, Baise, Guangxi, China



Objective: The aim of this study was to observe the impacts of the specific cyclooxygenase-2 inhibitor celecoxib on cardiac structures, functions, and inflammatory factors during the process of pressure overload–induced
myocardial hypertrophy.

Methods: Twenty-four male Sprague Dawley rats were randomly divided into 3 groups: the sham operation group, the surgery group, and the celecoxib group. The model was established according to the abdominal aortic
coarctation method.

Results: At 16 weeks, rats in the celecoxib group were fed a celecoxib-mixed diet (10 mg/kg) for 8 consecutive weeks. At week 24 after model establishment, the cardiac structures and functions were observed; changes in the levels of tumor necrosis factor (TNF)-α, transforming growth factor (TGF)-β, prostaglandin E2 (PGE2), C-reactive protein (CRP), and uric acid (UA) were detected; and the contents of Smad1/2/3 proteins (Smad1, Smad2, and Smad3)  were determined. Left ventricular mass index, the heart weight/body weight ratio, and TNF-α, TGF-β, PGE2, CRP, and UA levels of the celecoxib group were all significantly decreased relative to those of the surgery group (P < .05); moreover, the cardiac functions were significantly improved compared to those of the surgery group (P < .05).

Conclusions: These results show that inflammatory factors are involved in the myocardial hypertrophy process and that celecoxib may reverse myocardial hypertrophy through a variety of pathways.


Abbate A, Salloum FN, Ockaili RA, et al. 2007. Improvement of cardiac function with parecoxib, a cyclo-oxygenase-2 inhibitor, in a rat model of ischemic heart failure. J Cardiovasc Pharmacol 49:416-8.

Anversa P, Hagopian M, Loud AV. 1973. Quantitative radioautographic localization of protein synthesis in experimental cardiac hypertrophy. Lab Invest 29:282-92.

Bisping E, Wakula P, Poteser M, Heinzel FR. 2014. Targeting cardiac hypertrophy: toward a causal heart failure therapy. J Cardiovasc Pharmacol 64:293-305.

Buja LM, Vela D. 2008. Cardiomyocyte death and renewal in the normal and diseased heart. Cardiovasc Pathol 17:349-74.

Bujak M, Dobaczewski M, Chatila K, et al. 2008. Interleukin-1 receptor type I signaling critically regulates infarct healing and cardiac remodeling. Am J Pathol 173:57-67.

Castro V, Grisdale-Helland B, Helland SJ, et al. 2013. Cardiac molecular-acclimation mechanisms in response to swimming-induced exercise in Atlantic salmon. PLoS One 8:e55056.

Chan FK. 2006. Primer: managing NSAID-induced ulcer complications—balancing gastrointestinal and cardiovascular risks. Nat Clin Pract Gastroenterol Hepatol 3:563-73.

Chao TF, Liu CJ, Chen SJ, et al. 2013. The association between the use of non-steroidal anti-inflammatory drugs and atrial fibrillation: a nationwide case-control study. Int J Cardiol 168:312-6.

Cochain C, Auvynet C, Poupel L, et al. 2012. The chemokine decoy receptor D6 prevents excessive inflammation and adverse ventricular remodeling after myocardial infarction. Arterioscler Thromb Vasc Biol 32:2206-13.

Deftereos S, Bouras G. 2014. Editorial: targeting inflammation in cardiovascular disease. Med Chem 10:641-2.

Fujisawa N, Nakayama SM, Ikenaka Y, Ishizuka M. 2014. TCDD-induced chick cardiotoxicity is abolished by a selective cyclooxygenase-2 (COX-2) inhibitor NS398. Arch Toxicol 88:1739-48.

Janczewski AM, Kadokami T, Lemster B, Frye CS, McTiernan CF, Feldman AM. 2003. Morphological and functional changes in cardiac myocytes isolated from mice overexpressing TNF-alpha. Am J Physiol Heart Circ Physiol 284:H960-9.

Javadov S, Jang S, Agostini B. 2014. Crosstalk between mitogen-activated protein kinases and mitochondria in cardiac diseases: therapeutic perspectives. Pharmocol Ther 144:202-5.

Jugdutt BI. 2009. Limiting fibrosis after myocardial infarction. N Engl J Med 360:1567-9.

Krum H, Swergold G, Gammaitoni A, et al. 2012. Blood pressure and cardiovascular outcomes in patients taking nonsteroidal antiinflammatory drugs. Cardiovasc Ther 30:342-50.

Morales A, Gao W, Lu J, Xing J, Li J. 2012. Muscle cyclo-oxygenase-2 pathway contributes to the exaggerated muscle mechanoreflex in rats with congestive heart failure. Exp Physiol 97:943-54.

Parish RC, Evans JD. 2008. Inflammation in chronic heart failure. Ann Pharmacother 42:1002-61.

Regitz-Zagrosek V, Seeland U. 2011. Sex and gender differences in myocardial hypertrophy and heart failure. Wien Med Wochenschr 161:109-16.

Tsutamoto T, Wada A, Matsumoto T, et al. 2001. Relatinship between tumor necrosis factor-alpha production and oxidative stress in the failing hearts of patients with dilated cardiomyopathy. J Am Coll Cardiol 37:2086-92.

Voloshenyuk TG, Hart AD, Khoutorova E, Gardner JD. 2011. TNF-α increases cardiac fibroblast lysyl oxidase expression through TGF-β and PI3Kinase signaling pathways. Biochem Biophys Res Commun 413:370-5.

Wang Y, Li C, Liu Z, et al. 2014. DanQi Pill protects against heart failure through the arachidonic acid metabolism pathway by attenuating different cyclooxygenases and leukotrienes B4. BMC Complement Altern Med 14:67.



How to Cite

Xie, Z., Wang, S., Liang, Z., Zeng, L., Lai, R., Ye, Z., & Liao, P. (2019). Impacts of a Specific Cyclooxygenase-2 Inhibitor on Pressure Overload–Induced Myocardial Hypertrophy in Rats. The Heart Surgery Forum, 22(6), E432-E437.




Most read articles by the same author(s)